Miroculus

The company's core offering is the Miro Canvas, a compact, cartridge-based platform that automates Next-Generation Sequencing (NGS) sample preparation. This system utilizes digital microfluidics technology, which employs electromechanical forces to move droplets within a disposable cartridge, integrating steps like thermal cycling and magnetic bead cleanups. The primary benefit for its clients—which include research laboratories, hospitals, and scientists—is the reduction of manual labor, reagent usage, and protocol times, enabling on-demand processing without the need for large, complex robotic systems. The Miro Canvas supports both short and long-read sequencing platforms, making it a flexible tool for labs engaged in genomics. The business model centers on the sale of the Miro Canvas instrument and the recurring revenue from its proprietary, single-use cartridges.

Miroculus's journey includes several key milestones. It initially focused on developing a microRNA-based test for early cancer detection before broadening its scope to automating entire genomic protocols. The company secured over $48 million in funding across multiple rounds, with notable investors including Cota Capital and Nazca. A significant strategic move was the acquisition of Kapplex in 2016, which brought in the digital microfluidic technology that became central to the Miro Canvas platform. The Miro Canvas was commercially launched in 2022. In March 2023, Miroculus was acquired by INTEGRA Biosciences, a move intended to leverage Miroculus's expertise in genomics and expand INTEGRA's automation offerings.